Kapa Biosystems and VWR International, LLC announced today that they
have entered into a non-exclusive North American distribution agreement
for Kapa Biosystems' line of next-generation PCR reagents. Kapa
Biosystems employs a high-throughput molecular evolution technology
platform to engineer DNA-modifying enzymes for applications in DNA
amplification, next-generation sequencing, and molecular diagnostics.
Under the terms of the agreement, VWR has the rights to distribute Kapa
Biosystems' portfolio of innovative products for applications such as
high fidelity PCR, fast PCR, long range PCR, whole blood PCR, crude
sample PCR, and single protocol PCR. VWR, a global laboratory supply and
distribution company with worldwide sales in excess of $3.7 billion in
2008, enables the advancement of the world’s most critical research
through the distribution of a highly diversified product line to most of
the top pharmaceutical and biotech companies, as well as industrial,
educational and governmental organizations.
“Kapa's agreement with VWR will
significantly expand our ability to offer the benefits of these novel
products to the broader life sciences research community.”